Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Md/D and Raloxifene 60mg/D For The Prevention Of Bone Loss In Postmenopausal Women.

Trial Profile

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Md/D and Raloxifene 60mg/D For The Prevention Of Bone Loss In Postmenopausal Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2016

At a glance

  • Drugs Lasofoxifene (Primary) ; Raloxifene
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CORAL
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Apr 2016 Results comparing efficacy of Raloxifene and Lasofoxifene presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 06 Apr 2016 According to a Sermonix Pharmaceuticals media release, the company will present data from this study at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease (WCO-IOF-ESCEO)
    • 09 Oct 2015 Results will be presented at the upcoming American Society for Bone and Mineral Research Annual Meeting (ASBMR), as per Sermonix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top